Business Description
Biosergen AB
ISIN : SE0016013460
Compare
Compare
Traded in other countries / regions
BIOSGN.Sweden8N1.Germany IPO Date
2021-07-01Description
Biosergen AB is a biotech company developing innovative antifungal drugs based on latest biopharmaceutical research and development from laboratory facilities in Trondheim, Norway, and several other places worldwide. The company is developing BSG005, a potentially disruptive antifungal drug, which has demonstrated significant safety and potency advantages over competing antifungals.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | No Debt | |||||
| Equity-to-Asset | 0.8 | |||||
| Piotroski F-Score | 4/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | -30.1 | |||||
| 3-Year EPS without NRI Growth Rate | -26.9 | |||||
| 3-Year FCF Growth Rate | -54 |
Momentum Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 54.27 | |||||
| 9-Day RSI | 50.51 | |||||
| 14-Day RSI | 49.97 | |||||
| 6-1 Month Momentum % | 154.03 | |||||
| 12-1 Month Momentum % | 7.74 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 5.1 | |||||
| Quick Ratio | 5.1 | |||||
| Cash Ratio | 3.59 | |||||
| Days Payable | 2766.83 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -24.9 | |||||
| Shareholder Yield % | -29.55 |
Profitability Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROE % | -201.32 | |||||
| ROA % | -150.32 | |||||
| ROIC % | -272.62 | |||||
| ROC (Joel Greenblatt) % | -364.43 | |||||
| ROCE % | -200.26 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PB Ratio | 7.59 | |||||
| Price-to-Tangible-Book | 5.36 | |||||
| EV-to-EBIT | -3.76 | |||||
| EV-to-Forward-EBIT | -5.5 | |||||
| EV-to-EBITDA | -3.76 | |||||
| EV-to-FCF | -4.01 | |||||
| Price-to-Net-Current-Asset-Value | 5.36 | |||||
| Earnings Yield (Greenblatt) % | -26.59 | |||||
| FCF Yield % | -19.97 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Biosergen AB Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | |||
| EPS (TTM) (€) | -0.018 | ||
| Beta | 1.74 | ||
| Volatility % | 172.11 | ||
| 14-Day RSI | 49.97 | ||
| 14-Day ATR (€) | 0.004779 | ||
| 20-Day SMA (€) | 0.05402 | ||
| 12-1 Month Momentum % | 7.74 | ||
| 52-Week Range (€) | 0.0194 - 0.0874 | ||
| Shares Outstanding (Mil) | 142.39 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Biosergen AB Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Biosergen AB Stock Events
| Event | Date | Price(€) | ||
|---|---|---|---|---|
| No Event Data | ||||
Biosergen AB Frequently Asked Questions
What is Biosergen AB(FRA:8N1)'s stock price today?
The current price of FRA:8N1 is €0.05. The 52 week high of FRA:8N1 is €0.09 and 52 week low is €0.02.
When is next earnings date of Biosergen AB(FRA:8N1)?
The next earnings date of Biosergen AB(FRA:8N1) is 2025-03-28 Est..
Does Biosergen AB(FRA:8N1) pay dividends? If so, how much?
Biosergen AB(FRA:8N1) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers